NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference
November 18 2020 - 9:15AM
Business Wire
NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer
cell-based therapeutics company, today announced its participation
in the virtual 32nd Annual Piper Sandler Healthcare conference,
which takes place December 1-3, 2020. NantKwest Executive Chairman
Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock
will participate in institutional investor meetings on Tuesday,
December 1; meetings may be requested through Piper Sandler.
Additionally, a pre-recorded fireside chat with Dr. Soon-Shiong
and Mr. Adcock will be accessible beginning November 23, 2020 on
the Piper Sandler conference site and in the Investors section of
NantKwest’s website, NantKwest.com. The recording will be available
on the NantKwest website through December 31, 2020.
About NantKwest NantKwest (NASDAQ: NK) is an innovative,
clinical-stage immunotherapy company focused on harnessing the
power of the innate immune system to treat cancer and infectious
diseases. NantKwest is the leading producer of clinical dose forms
of off-the-shelf natural killer (NK) cell therapies. The activated
NK cell platform is designed to destroy cancer and virally-infected
cells. The safety of these optimized, activated NK cells—as well as
their activity against a broad range of cancers—has been tested in
phase I clinical trials in Canada and Europe, as well as in
multiple phase I and II clinical trials in the United States. By
leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of
multiple, clinical-stage, immuno-oncology programs, NantKwest’s
goal is to transform medicine by bringing novel NK cell-based
therapies to routine clinical care. NantKwest is a member of the
NantWorks ecosystem of companies. For more information, please
visit www.nantkwest.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that NantKwest will be successful in improving the
treatment of cancer or other critical illnesses, including
COVID-19. Risks and uncertainties related to these endeavors
include, but are not limited to, obtaining FDA approval of
NantKwest’s NK cells and MSC as well as other therapeutics and
manufacturing challenges.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its Securities and Exchange Commission
filings, including in NantKwest’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2020. These forward-looking
statements speak only as of the date hereof, and we disclaim any
obligation to update these statements except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201118005496/en/
Jen Hodson NANT Jen@nant.com 562-397-3639
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024